Physician profile
David R Weldon
NPI 1619939527
$956.01
in general payments reported to CMS, 2019-2025
8 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.58 · 2023: $379 · 2024: $385 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $184.15 | 2023-2024 | Orladeyo |
| Blueprint Medicines Corporation | $159.18 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $147.50 | 2024 | Xolair |
| Pharming Healthcare, INC. | $122.01 | 2024 | Joenja |
| Takeda Pharmaceuticals U.S.A., INC. | $121.01 | 2023 | Cuvitru, Cinryze |
| Glaxosmithkline, LLC. | $95.65 | 2023 | Nucala |
| Astrazeneca Pharmaceuticals LP | $71.93 | 2024-2025 | Tezspire |
| Alk-Abello, INC | $54.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.